Abstract

Nonalcoholic fatty liver disease is the most common chronic liver disease and may progress to nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The molecular determinants of this pathogenic progression, however, remain largely undefined. Since liver tumorigenesis is driven by apoptosis, we examined the effect of overt hepatocyte apoptosis in a mouse model of NASH using mice lacking myeloid cell leukemia 1 (Mcl1), a pro-survival member of the BCL-2 protein family. Hepatocyte-specific Mcl1 knockout (Mcl1∆hep) mice and control littermates were fed chow or FFC (high saturated fat, fructose, and cholesterol) diet, which induces NASH, for 4 and 10 months. Thereafter, liver injury, inflammation, fibrosis, and tumor development were evaluated biochemically and histologically. Mcl1∆hep mice fed with the FFC diet for 4 months displayed a marked increase in liver injury, hepatocyte apoptosis, hepatocyte proliferation, macrophage-associated liver inflammation, and pericellular fibrosis in contrast to chow-fed Mcl1∆hep and FFC diet-fed Mcl1-expressing littermates. After 10 months of feeding, 78% of FFC diet-fed Mcl1∆hep mice developed liver tumors compared to 38% of chow-fed mice of the same genotype. Tumors in FFC diet-fed Mcl1∆hep mice were characterized by cytologic atypia, altered liver architecture, immunopositivity for glutamine synthetase, and histologically qualified as HCC. In conclusion, this study provides evidence that excessive hepatocyte apoptosis exacerbates the NASH phenotype with enhancement of tumorigenesis in mice.

Highlights

  • Obesity-related co-morbidities including non-alcoholic fatty liver disease (NAFLD) have paralleled the increasing prevalence of obesity and are a major public health concern

  • Chow-WT n = 6 mice; Chow-Mcl1Δhep n = 5 mice; FFC-WT n = 6 mice; FFC-Mcl1Δhep n = 6 mice. d mRNA expression of anti-apoptotic proteins in whole liver tissue of mice fed for 4 months

  • The present study tests the hypothesis that excessive hepatocyte apoptosis in fatty liver disease promotes liver

Read more

Summary

Introduction

Obesity-related co-morbidities including non-alcoholic fatty liver disease (NAFLD) have paralleled the increasing prevalence of obesity and are a major public health concern. NAFLD is currently the most common chronic liver disease with an estimated worldwide prevalence of 25%1. NAFLD encompasses a spectrum of liver conditions ranging from steatosis to a more severe and progressive disease termed nonalcoholic steatohepatitis (NASH). NASH is characterized by hepatocyte injury and NASH-related cirrhosis develop HCC over 3 years in contrast to 0–3% of NAFLD cohort without cirrhosis followed for a period of 10–20 years[3]. Cirrhosis is associated with an increased risk but at the same time is not required for HCC development in NAFLD. Up to 45–50% of patients with NAFLD-related HCC develop the malignancy in the absence of cirrhosis[3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call